Downregulated expression of genes mapping on chromosome 9 in chronic myeloid leukemia cases bearing genomic deletions on der(9)

Leukemia

Volumn 23, Issue 4, 2009, Pages 813-816

  Albano, F ^a   Anelli, L ^a   Zagaria, A ^a   Pannunzio, A ^a   Liso, V ^a   Rocchi, M ^a   Specchia, G ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANKYRIN; ENDOPHILIN; GENE PRODUCT; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMATINIB; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE; PROTEIN KINASE PKN BETA; PROTEIN SH3; PROTEINASE; SUPPRESSOR OF CYTOKINE SIGNALING; TORSIN FAMILY 1 MEMBER B; UBIQUITIN SPECIFIC PROTEASE 20; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 9; CHROMOSOME ANALYSIS; CHROMOSOME LOSS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; DRUG TREATMENT FAILURE; FEMALE; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENE LOSS; GENE MAPPING; GENE SEQUENCE; HUMAN; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

EID: 64849084451     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.311     Document Type: Article

References (8)

1. Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic factor in chronic myeloid leukaemia. Blood 2001; 98 1732-1738.
2. Huntly BJ, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C et al Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003a; 102: 2205-2212.
3. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005; 105: 2281-2286.
4. Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: Deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003b; 102: 1160-1168.
5. Albano F, Anelli L, Zagaria A, Archidiacono N, Liso V, Specchia G et al. 'Home-brew' FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia. Cancer Genet Cytogenet 2007; 174: 121-126.
6. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002; 30 e36.
7. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005; 8: 355-368.
8. Fourouclas N, Campbell PJ, Bench AJ, Swanton S, Baxter EJ, Huntly BJ et al. Size matters: The prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia. Haematologica 2006; 91: 952-955.